GLUEMonte Rosa Therapeutics, Inc.
Price
+63%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
A flag to check, growth fading, the market against it.
We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, in effect editing the human proteome. MGDs function by inducing the engagement of an E3 ligase, such as cereblon, with defined structural features on surfaces of target proteins.
In the company’s own words · 10-K filed Mar 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Monte Rosa Therapeutics, Inc. (GLUE) reported revenue of $9.0M in Q2 2026 (quarter ended Jun 30, 2026), down 61% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $124M (+64% year on year) and net income −$39M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On October 1, 2026, the Company announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of NLRP3/IL-1-driven inflammatory diseases.Regulation FD disclosure · Form 8-K
- Sep 8, 2026As previously disclosed, the Company is party to a global exclusive development and commercialization license agreement (the “Novartis Agreement”) with Novartis pursuant to which Novartis has exclusive worldwide rights to develop, manufacture and commercialize VAV1-directed MGDs, including MRT-6160 (DDY391)Regulation FD disclosure · Form 8-K
- Aug 6, 2026Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.